MediBeacon is developing and commercializing biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease
Portfolio includes a renal function system that uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light
Highlights
Pivotal clinical study underway to directly measure and monitor Glomerular Filtration Rate (GFR) or kidney function
First-in-human studies focused on GI permeability completed in patients with active Crohn's disease
Clinical study IDE and IRB approvals in place to image eye vasculature in macular degeneration and diabetic retinopathy
Clinical study collaboration is in process to visualize the ureters in laparoscopic abdominal surgery
The network BioGenerator has is really invaluable and their active support from pre-company licensing through our Series A round was critical in getting the company to where it is today.
Steve Hanley Co-Founder and CEO, MediBeacon
BioGenerator Contributions
BioGenerator Ventures led the company's first financing and has invested in multiple rounds
BioGenerator provided full due diligence to side-by-side and follow-on investors, facilitating the company's early financings
MediBeacon initially leveraged the BioGenerator Labs for operations
Charlie Bolten, Senior Managing Director of BioGenerator Ventures, served on the company's board
